Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stake Lessened by Victory Capital Management Inc.

Victory Capital Management Inc. cut its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 35.8% in the 1st quarter, HoldingsChannel reports. The fund owned 4,558 shares of the company’s stock after selling 2,541 shares during the period. Victory Capital Management Inc.’s holdings in Axsome Therapeutics were worth $258,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. BlackRock Inc. boosted its holdings in shares of Axsome Therapeutics by 0.7% in the fourth quarter. BlackRock Inc. now owns 2,279,766 shares of the company’s stock valued at $185,733,000 after acquiring an additional 16,007 shares in the last quarter. Iridian Asset Management LLC CT boosted its holdings in shares of Axsome Therapeutics by 19.8% in the fourth quarter. Iridian Asset Management LLC CT now owns 2,064,158 shares of the company’s stock valued at $168,167,000 after acquiring an additional 341,335 shares in the last quarter. Alliancebernstein L.P. boosted its holdings in shares of Axsome Therapeutics by 10.2% in the fourth quarter. Alliancebernstein L.P. now owns 597,798 shares of the company’s stock valued at $48,703,000 after acquiring an additional 55,525 shares in the last quarter. Hillhouse Capital Advisors LTD. bought a new position in shares of Axsome Therapeutics in the fourth quarter valued at approximately $29,329,000. Finally, Norges Bank bought a new position in shares of Axsome Therapeutics in the fourth quarter valued at approximately $22,397,000. Institutional investors and hedge funds own 60.61% of the company’s stock.

In other news, Director Mark Coleman bought 500 shares of the stock in a transaction that occurred on Wednesday, May 12th. The shares were acquired at an average cost of $58.15 per share, for a total transaction of $29,075.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 26.10% of the company’s stock.

Shares of AXSM opened at $67.57 on Friday. The business’s fifty day simple moving average is $57.49. Axsome Therapeutics, Inc. has a 12 month low of $50.05 and a 12 month high of $90.00. The firm has a market cap of $2.54 billion, a price-to-earnings ratio of -25.40 and a beta of 2.53. The company has a current ratio of 7.61, a quick ratio of 7.61 and a debt-to-equity ratio of 0.50.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings results on Sunday, May 9th. The company reported ($0.78) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.83) by $0.05. Research analysts anticipate that Axsome Therapeutics, Inc. will post -3.74 EPS for the current year.

AXSM has been the subject of several recent research reports. Morgan Stanley increased their target price on shares of Axsome Therapeutics from $104.00 to $105.00 and gave the company an “overweight” rating in a research note on Wednesday, May 26th. Berenberg Bank started coverage on shares of Axsome Therapeutics in a research report on Thursday. They issued a “buy” rating and a $112.00 price target for the company.
HC Wainwright upped their price target on shares of Axsome Therapeutics from $210.00 to $225.00 and gave the company a “buy” rating in a research report on Tuesday, April 27th. Mizuho reduced their price target on shares of Axsome Therapeutics from $120.00 to $118.00 and set a “buy” rating for the company in a research report on Tuesday, March 2nd. Finally, BTIG Research restated a “buy” rating on shares of Axsome Therapeutics in a research report on Wednesday, May 12th. One research analyst has rated the stock with a sell rating and nine have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $130.86.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation.

Read More: Dow Jones Industrial Average (DJIA)

Want to see what other hedge funds are holding AXSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics, Inc. (NASDAQ:AXSM).

Institutional Ownership by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.